Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Globally, respiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality. Natural infection offers limited protection against reinfection. Passive immunization with RSV-specific antibody can protect infants against severe lower respiratory tract infection (LRTI). This suggests that vaccine-induced antibody could benefit infants and therefore supports maternal vaccination as a potential strategy for protecting young infants. The duration of such protection will dictate the need and timing for additional infant vaccines which are under development. For high-risk groups of passive immunization with monoclonal antibodies continues to be standard approach. With novel monoclonal antibodies that have a longer half-life and lower cost the strategy may be extended to healthy infants.

Original publication





Book title

Pediatric Vaccines and Vaccinations: A European Textbook: Second Edition

Publication Date



293 - 296